Table 2.
Univariate and multivariate analysis of progression-free survival
| Clinical parameter |
Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|---|
| n (% ) | Median (months) | P value | HR (95% CI) | P value | |
| Age |
|
|
|
|
|
| < 65 |
38 (82, 6%) |
14, 1 |
0, 076 |
NS |
NS |
| ≥ 65 |
8 (17, 4%) |
23, 2 |
|
|
|
| Histopathologic cell type |
|
|
|
|
|
| Serous |
24 (52, 2%) |
13, 8 |
0, 028 |
NS |
NS |
| Others |
22 (47, 8%) |
23, 2 |
|||
| Residual tumor size |
|
|
|
|
|
| <1 cm |
19 (41, 3%) |
21, 8 |
0, 054 |
NS |
NS |
| > 1 cm |
27 (58, 7%) |
10, 7 |
|
|
|
| Performance status (ECOG) |
|
|
|
|
|
| 0-1 |
43 (93, 5%) |
16, 7 |
0, 564 |
|
|
| 2 |
3 (6, 5%) |
22, 0 |
|
|
|
| Tumor grade |
|
|
|
|
|
| G1, G2 |
21 (45, 6%) |
12, 9 |
0, 981 |
|
|
| G3, unknown |
25 (54, 4%) |
17, 5 |
|
|
|
| E-cadherin membranous |
|
|
|
|
|
| Negative |
7 (15, 2%) |
16, 7 |
0, 775 |
|
|
| Positive |
39 (84, 8%) |
15, 9 |
|
|
|
| E-cadherin cytoplasmic |
|
|
|
|
|
| Negative |
1 (2, 2%) |
|
|
|
|
| Positive |
45 (97, 8%) |
- |
- |
|
|
| β-catenin membranous |
|
|
|
|
|
| Normal |
21 (45, 6%) |
9, 9 |
0, 024 |
2, 19 (1, 09-4, 39) |
0, 028 |
| Decreased |
25 (54, 4%) |
22, 8 |
|
|
|
| β-catenin cytoplasmic |
|
|
|
|
|
| Negative |
27 (58, 7%) |
15, 4 |
0, 806 |
|
|
| Positive |
19 (41, 3%) |
16, 7 |
|
|
|
| β-catenin nuclear |
|
|
|
|
|
| Negative |
46 (100, 0%) |
- |
- |
|
|
| Positive |
0 (0, 0%) |
|
|
|
|
| WNT-1 |
|
|
|
|
|
| Normal |
31 (67, 4%) |
13, 5 |
0, 898 |
|
|
| Decreased | 15 (32, 6%) | 18, 8 | |||
NS - non significant.